{
    "clinical_study": {
        "@rank": "13393", 
        "arm_group": [
            {
                "arm_group_label": "control patients", 
                "description": "BMI and age matched healthy male subjects"
            }, 
            {
                "arm_group_label": "hypogonadism patients", 
                "description": "unconfounded group of patients with hypogonadism"
            }
        ], 
        "biospec_descr": {
            "textblock": "Serum and plasma samples"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "The aim of this study is to investigate the markers of bone mineral metabolism in an\n      unconfounded group of patients with hypogonadism and to search for a relationship between\n      endothelial dysfunction and insulin resistance."
        }, 
        "brief_title": "Bone Mineral Markers in Hypogonadism", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hypogonadotropic Hypogonadism", 
            "Endothelial Dysfunction", 
            "Insulin Resistance"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypogonadism", 
                "Insulin Resistance"
            ]
        }, 
        "detailed_description": {
            "textblock": "Cardiometabolic disorders are prevalent in patients with hypogonadism. Endothelial\n      dysfunction and insulin resistance are used in determining cardiovascular risk. The role of\n      markers of bone mineral metabolism in hypogonadism is not clearly presented.\n\n      49 male patients with hypogonadotropic hypogonadism (HH) and 43 BMI and age matched healthy\n      male subjects were enrolled. Osteoprotegerin (OPG), fibroblast growth factor-23 (FGF-23),\n      vitamin D and asymmetric dimethylarginine (ADMA) levels were measured. The insulin\n      sensitivity was estimated by homeostatic model assessment-insulin resistance (HOMA-IR)\n      formula."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  male patients with hypogonadotropic hypogonadism\n\n          -  being under the age of 45 and over the age of 18\n\n          -  not previously given testosterone or human chorionic gonadotropin therapy\n\n          -  not have any chronic metabolic disorders or organ dysfunction\n\n        Exclusion Criteria:\n\n          -  female patients\n\n          -  Other reasons hipogondism\n\n          -  receive any treatment of hypogonadism\n\n          -  presence of comorbid diseases"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The study group was selected from the male subjects with hypogonadotropic hypogonadism who\n        were not previously given testosterone or human chorionic gonadotropin therapy. The\n        patients did not have any chronic metabolic disorders or organ dysfunction. Forty three\n        age and BMI matched male volunteers were enrolled as control subjects."
            }
        }, 
        "enrollment": {
            "#text": "92", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02062307", 
            "org_study_id": "cmeric2000"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Mitogens", 
                "N,N-dimethylarginine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hypogonadism", 
            "Asymmetric Dimethyl Arginine", 
            "Osteoprotegerin", 
            "Fibroblast Growth Factor", 
            "Vitamin D"
        ], 
        "lastchanged_date": "February 12, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ankara", 
                    "country": "Turkey", 
                    "zip": "06018"
                }, 
                "name": "Gulhane School of Medicine"
            }
        }, 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_groups": "2", 
        "official_title": "Osteoprotegerin, Fibroblast Growth Factor 23 and Vitamin D3 Levels in Male Patients With Hypogonadism", 
        "overall_official": {
            "affiliation": "Gulhane School of Medicine Department of Endocrinology", 
            "last_name": "Coskun Meric", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Turkey: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "investigate the markers of bone mineral metabolism in patients with hypogonadism", 
            "measure": "Osteoprotegerin, Fibroblast Growth Factor 23 and Vitamin D3 levels", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02062307"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Gulhane School of Medicine", 
            "investigator_full_name": "Coskun Meric", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "relationship between bone mineral metabolism and endothelial dysfunction, insulin resistance", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "source": "Gulhane School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gulhane School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}